Detail akcie Amphastar Pharmactc online

Business Summary: Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Amphastar Pharmaceuticals Inc revenues increased 14% to $732M. Net income increased 16% to $159.5M. Revenues reflect BAQSIMI segment increase from $51.2M to $126.9M, United States segment increase of 11% to $707.7M, France segment increase from $4.7M to $19.9M. Net income benefited from Other Nonoperating Income (Expense) increase from $3.9M (expense) to $4.1M (income).